Agree. But being listed on the Nasdaq at the time of OSA results (assuming they're positive) would IMO cause much more of a price reaction than if it was an ASX-listed company only. The American market seems to understand biotechs much more than our market. And if there aren't enough ADRs on the Nasdaq they would be forced to buy on the ASX.
IHL Price at posting:
61.5¢ Sentiment: Buy Disclosure: Held